PMID- 36625486
OWN - NLM
STAT- MEDLINE
DCOM- 20230310
LR  - 20230327
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 129
IP  - 7
DP  - 2023 Apr 1
TI  - A novel prognostic system combining carbonic anhydrase II and preoperative CA19-9 
      for intrahepatic cholangiocarcinoma after curative resection.
PG  - 1030-1040
LID - 10.1002/cncr.34639 [doi]
AB  - BACKGROUND: The role of carbonic anhydrase II (CAII) in intrahepatic 
      cholangiocarcinoma (ICC) was investigated and a novel prognostic system combining 
      CAII and preoperative carbohydrate antigen 19-9 (CA19-9) was established to 
      predict the survival of patients with ICC after curative resection. METHODS: A 
      total of 110 patients who underwent curative-intent resection for ICC between 
      2012 and 2020 were retrospectively analyzed. CAII in tumor and peritumor regions 
      was examined by immunohistochemistry, and the relationships between 
      clinicopathological factors and the prognostic value of CAII and CA19-9 were 
      analyzed. RESULTS: CAII was frequently downregulated in ICC tissues (p < .001). 
      Multivariate analyses indicated that showed that both low CAII expression level 
      and preoperative CA19-9 >/=236 U/ml were independent risk factors for overall 
      survival (OS) and recurrence-free survival (RFS) in patients with ICC after 
      radical resection. Survival analysis revealed that patients with high CAII and 
      low CA19-9 were significantly associated with a better OS and RFS (p < .001). The 
      time-dependent receiver operating characteristic curves showed that CAII + CA19-9 
      had better prognostic predictive ability than CAII or CA19-9 alone. The nomogram 
      constructed on independent factors including T stage, lymph node metastasis, 
      CA19-9 (continuous variable), and CAII achieved C-indexes of 0.754 (95% CI, 
      0.701-0.807) and 0.730 (0.674-0.785) for OS and RFS, respectively. The 
      calibration curve revealed acceptable agreement between actual and predicted OS 
      and RFS. CONCLUSIONS: The combination of CAII and preoperative CA19-9 is a novel 
      and useful prognostic tool for predicting the survival of patients with ICC after 
      curative resection and guiding clinical decisions. PLAIN LANGUAGE SUMMARY: 
      Carbonic anhydrase II (CAII) was frequently downregulated in intrahepatic 
      cholangiocarcinoma (ICC) tissues. Survival analysis revealed that CAII is a novel 
      independent factor for prognosis in patients with ICC after curative resection. 
      CAII could be a useful prognostic marker for patients with ICC after surgery. The 
      combination of CAII and preoperative carbohydrate antigen 19-9 is a novel and 
      useful prognostic tool for predicting the survival of patients with ICC after 
      curative resection and guiding clinical decisions.
CI  - (c) 2023 American Cancer Society.
FAU - Zhang, Jiawei
AU  - Zhang J
AD  - Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated 
      Hospital, Fujian Medical University, Quanzhou, China.
FAU - Huang, Qiming
AU  - Huang Q
AD  - Department of Medical Imaging, the Second Affiliated Hospital, Fujian Medical 
      University, Quanzhou, China.
FAU - Yang, Yi
AU  - Yang Y
AD  - Department of Radiology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Zhang, Jiahui
AU  - Zhang J
AD  - Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated 
      Hospital, Fujian Medical University, Quanzhou, China.
FAU - Fang, Xueting
AU  - Fang X
AD  - Department of Pathology, the Second Affiliated Hospital, Fujian Medical 
      University, Quanzhou, China.
FAU - Yang, Yubin
AU  - Yang Y
AD  - Department of Pathology, the Second Affiliated Hospital, Fujian Medical 
      University, Quanzhou, China.
FAU - Liang, Huifang
AU  - Liang H
AD  - Department of Hepatobiliary Surgery, Tongji Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated 
      Hospital, Fujian Medical University, Quanzhou, China.
FAU - Wang, Yanjun
AU  - Wang Y
AUID- ORCID: 0000-0002-8178-9925
AD  - Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated 
      Hospital, Fujian Medical University, Quanzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230110
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (CA-19-9 Antigen)
RN  - EC 4.2.1.- (Carbonic Anhydrase II)
RN  - 0 (Carbohydrates)
SB  - IM
MH  - Humans
MH  - Prognosis
MH  - CA-19-9 Antigen
MH  - Retrospective Studies
MH  - Carbonic Anhydrase II
MH  - *Cholangiocarcinoma/pathology
MH  - Bile Ducts, Intrahepatic/pathology
MH  - *Bile Duct Neoplasms
MH  - Carbohydrates
OTO - NOTNLM
OT  - carbohydrate antigen 19-9
OT  - carbonic anhydrase II
OT  - intrahepatic cholangiocarcinoma
OT  - nomogram
OT  - survival
EDAT- 2023/01/11 06:00
MHDA- 2023/03/11 06:00
CRDT- 2023/01/10 08:12
PHST- 2022/12/09 00:00 [revised]
PHST- 2022/08/20 00:00 [received]
PHST- 2022/12/10 00:00 [accepted]
PHST- 2023/01/11 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
PHST- 2023/01/10 08:12 [entrez]
AID - 10.1002/cncr.34639 [doi]
PST - ppublish
SO  - Cancer. 2023 Apr 1;129(7):1030-1040. doi: 10.1002/cncr.34639. Epub 2023 Jan 10.